Robotic Surgery in India: Precision, Price, and the Limits of Scale

Where Robotics Clearly Wins—and Where the Evidence Is Mixed

Robotic surgery’s value is procedure-specific, not universal. Evidence from international and Indian practice shows clear advantages in operations where anatomy is confined and precision is paramount—most notably rectal cancer surgery, prostatectomy, complex pelvic procedures, and certain pancreatic and oesophageal resections. In these cases, enhanced visualisation and wristed instruments translate into better nerve preservation, lower blood loss, and faster recovery.

However, for many routine procedures, outcomes between robotics and advanced laparoscopy are comparable. In some operations, robotic surgery may even increase operative time without significantly improving results. This explains why adoption patterns vary sharply by specialty: gastrointestinal, urology, and gynaecologic oncology dominate robotic volumes, while other branches adopt selectively.

This nuance matters because indiscriminate expansion risks turning robotics into a marketing differentiator rather than a clinical one. Surgeons who resist over-robotisation often point to cost-effectiveness and training dilution as concerns. The most mature centres therefore deploy robotics selectively—where outcome gains justify the expense—rather than as a default for all minimally invasive surgery.

Public Hospitals Catching Up to a Private-Led Technology

Despite AIIMS’ early start, adoption of robotic surgery across India has been uneven. High upfront costs, procurement hurdles, and limited training initially confined the technology to private hospitals. Today, around 90% of India’s surgical robots are still housed in private facilities, with government hospitals accounting for just 10%.

That balance is slowly shifting. Alongside AIIMS New Delhi, public institutions such as PGI Chandigarh, SGPGI Lucknow, JIPMER Puducherry, AIIMS Jodhpur, AIIMS Rishikesh, and SMS Medical College Jaipur have established active robotic surgery programmes. Nationally, over 100 robotic systems are now operational, and experts estimate that 50,000–60,000 robotic surgeries are performed in India each year.

According to Dr Vivek Bindal, chairman of the Clinical Robotic Surgery Association of India, the initial barriers were not just technological but structural. Early systems were expensive, training required overseas travel, and only a handful of hospitals could absorb both costs. Over time, domestic training capacity expanded and more systems entered the market, lowering entry barriers.

The Training Bottleneck: Why Surgeons, Not Robots, Are the Real Constraint

India’s robotic-surgery expansion is constrained less by machines than by trained hands behind the console. A robotic system can be installed in months; developing a confident robotic surgeon takes years. Most specialties require a learning curve of 20–50 supervised cases before outcomes stabilise, and far more before surgeons are comfortable handling complications robotically rather than converting mid-procedure.

At present, India lacks a nationally standardised accreditation framework for robotic surgery. Training pathways are fragmented: some surgeons train through manufacturer-led modules, others through overseas fellowships, and a smaller number through structured programmes at institutions like All India Institute of Medical Sciences (AIIMS) and select private teaching hospitals. This patchwork creates uneven skill depth and variable outcomes across centres.

The constraint is sharper in public hospitals. Government surgeons rotate frequently, teaching loads are heavy, and protected time for console training is limited. A robot may be present, but utilisation suffers if only one or two surgeons are credentialed to use it. By contrast, private hospitals concentrate caseloads among a smaller group of surgeons, allowing skills to compound quickly.

This explains a paradox now visible across India: Tier-II hospitals may own robotic systems but plateau at low volumes, while a handful of metropolitan centres perform hundreds of cases annually. Until training capacity scales—through domestic fellowships, simulation labs, and formal credentialing—robotic surgery’s diffusion will remain uneven, regardless of capital investment.

Why Public Procurement Slows Robotics—even When Funds Exist

Public hospitals do not simply “buy” robotic systems; they navigate multi-year procurement and audit frameworksbuilt for static equipment, not fast-evolving medical technology. Capital approvals, tendering, and vendor evaluation can take 18–36 months—long enough for a system to be technically outdated by the time it is installed.

Lifecycle costs compound the problem. The purchase price—often several crores—is only the first line item. Annual maintenance contracts, instrument replacement, software upgrades, and consumables can match or exceed the original cost over a decade. Public budgeting, however, separates capital and recurring expenditure into different heads, making it difficult to commit to long-term maintenance at the time of purchase.

There are also operational frictions. In several government hospitals, robotic systems have faced downtime due to delayed maintenance approvals, shortages of trained technicians, or slow procurement of disposable instruments. Unlike private hospitals, which can renegotiate contracts quickly, public institutions are bound by rigid tender conditions.

The result is not just slower adoption but lower utilisation, which in turn inflates per-procedure costs and weakens the case for expansion. This is why robotics remains concentrated in flagship public centres rather than scaling evenly across the government system.

Insurance, Competition, and COVID: Why Adoption Accelerated

Three forces accelerated robotic surgery’s spread beyond elite centres.

• First was insurance acceptance. Around 2019, robotic procedures began to find formal recognition within health insurance policies following regulatory clarity from the Insurance Regulatory and Development Authority of India (IRDAI). Even partial reimbursement made robotic options viable for a larger pool of patients.
• Second was the COVID-19 pandemic. Hospitals prioritised minimally invasive procedures that reduced complications, shortened hospital stays, and lowered infection risk. Robotic systems aligned neatly with these goals, reinforcing their clinical and operational appeal.
• Third was competition.

Domestic Surgical Robotics: What “Make-in-India” Actually Changes on the Ground

For nearly two decades, robotic surgery in India effectively meant one thing: dependence on a single multinational platform—Intuitive, maker of the da Vinci system. That dominance shaped not just pricing, but training access, maintenance timelines, consumable costs, and upgrade cycles, leaving Indian hospitals as technology takers rather than shapers.

The entry of indigenous systems—most prominently SSI Mantra, developed by SS Innovations—has begun to change that equation in practical, if uneven, ways.

Where Indigenous Systems Make a Real Difference

Capital and maintenance economics:

Hospital administrators consistently point to lower upfront acquisition costs and locally anchored servicing as the primary advantage of Indian-made systems. Unlike imported platforms that rely on overseas supply chains for spares and software upgrades, domestic systems reduce downtime risk and cut waiting periods for repairs—an issue that has previously kept expensive robots idle in both public and private hospitals.

Training localisation:

Domestic manufacturers have invested in India-based training centres, reducing reliance on overseas certification programmes. This matters disproportionately for public-sector surgeons and Tier-II city hospitals, where foreign training is often impractical due to cost, leave constraints, and cadre rotation.

Competitive pressure on pricing:

Even hospitals that continue to procure imported systems acknowledge a secondary effect: price discipline. The presence of Indian alternatives has forced renegotiation of service contracts, consumable pricing, and upgrade terms across the market—something that was virtually impossible under a single-supplier regime.

Where the Constraints Remain

Regulatory and outcomes data:

While domestic systems have received approvals from India’s medical device regulator, longitudinal outcome data across large, multi-centre cohorts remains limited compared to global incumbents. For surgeons and hospital boards, especially in oncology, this evidence gap slows full-scale switching.

Surgeon confidence and inertia:

Robotic surgery is not just a machine choice; it is a career-long skill investment. Many senior surgeons trained on established platforms are reluctant to retool unless systems demonstrate equivalence in ergonomics, precision, and reliability over hundreds of cases. This behavioural inertia explains why adoption, even when cost-effective, is gradual.

Export ambition vs domestic scale:

Indian manufacturers often frame robotics as an export opportunity to other middle-income countries. In practice, domestic scale is the harder test. India’s fragmented hospital market, uneven payer coverage, and public-procurement rigidity pose a more demanding proving ground than overseas sales.

What This Means for India’s Robotic Surgery Trajectory

Indigenous robotics does not guarantee rapid democratisation of robotic surgery—but it changes the slope of the curve. By lowering entry barriers, shortening service loops, and weakening monopoly pricing, domestic systems make it possible—though not inevitable—for robotic surgery to move beyond elite private hospitals.

Whether this potential translates into widespread access will depend less on technology and more on procurement reform, outcome transparency, and integration into public health financing. Without those, Indian robots risk becoming symbols of capability rather than instruments of scale.

Beyond Metros: Robotics Reaches Tier-I and Tier-II Cities

What is most striking now is not robotic surgery’s presence in flagship institutions, but its diffusion beyond metros. Hospitals in Tier-I and Tier-II cities such as Lucknow and Mysuru report hundreds of robotic procedures annuallyacross gynaecology, gastrointestinal surgery, urology, and oncology.

At AIIMS, robots are now routinely used for procedures involving the liver, bile ducts, pancreas, stomach, oesophagus, colon, kidneys, and endocrine organs. These include pancreaticoduodenectomy, gastrectomy, esophagectomy, colectomy, anterior resection for gastrointestinal malignancies, complex hernia reconstructions, kidney transplantation, and minimally invasive surgery for thyroid, parathyroid, adrenal, and pancreatic tumours.

Nationally, gastrointestinal and general surgery remains the largest contributor to robotic surgical volumes—a pattern that has held consistently over the years.

Administrators note that the appeal is not purely clinical. Shorter hospital stays improve bed turnover, while faster recovery reduces post-operative care costs—important considerations as hospitals operate under increasing financial pressure.

Outcomes, Costs, and the Affordability Question

Clinical studies cited by AIIMS surgeons suggest that robotic-assisted procedures are associated with around 50% lower postoperative pain, 30% shorter hospital stays, and nearly 40% lower surgical-site infection rates compared to traditional open surgery, largely due to smaller and more precise incisions.

Yet cost remains the central constraint. A single robotic system costs several crores of rupees, with substantial annual maintenance expenses. Training surgeons, nurses, and technicians adds to the investment.

The price difference is stark at the patient level. According to Dr Chumber, an open gallbladder surgery may cost ₹10,000–15,000. Laparoscopic surgery typically costs about ₹10,000 more due to infrastructure and staffing requirements. In contrast, robotic gallbladder surgery can add around ₹1 lakh to the bill in some hospitals with robotic tie-ups. While proponents expect costs to moderate over time as utilisation rises and competition deepens, affordability remains a live policy and equity issue—especially in a health system where most patients still pay out of pocket.

Why This Matters

Robotic surgery’s spread from elite public institutes to smaller city hospitals marks a structural shift in Indian healthcare. It reflects how technology, insurance policy, market competition, and clinical outcomes intersect to reshape medical practice. Yet the transition also exposes fault lines—between private and public capacity, between clinical benefit and affordability, and between technological promise and health-system equity.

As robotic systems become more common, the next phase of debate will centre not on whether the technology works, but who can access it, who pays for it, and how its benefits are distributed across India’s deeply unequal healthcare landscape.